中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

高通量测序在肝硬化患者腹水、血清及粪便微生物群检测中的应用

李真 张维 贾琳 胡中杰

娄鑫, 郜玉峰, 叶珺, 王殷秋, 管子姝, 邹桂舟. 聚乙二醇干扰素α-2a初治HBeAg阳性慢性乙型肝炎患者的效果及预测因素分析[J]. 临床肝胆病杂志, 2018, 34(5): 995-1000. DOI: 10.3969/j.issn.1001-5256.2018.05.014.
引用本文: 娄鑫, 郜玉峰, 叶珺, 王殷秋, 管子姝, 邹桂舟. 聚乙二醇干扰素α-2a初治HBeAg阳性慢性乙型肝炎患者的效果及预测因素分析[J]. 临床肝胆病杂志, 2018, 34(5): 995-1000. DOI: 10.3969/j.issn.1001-5256.2018.05.014.
Lou Xin, Gao YuFeng, Ye Jun, Wang YinQiu, Guan ZiShu, Zou GuiZhou. Clinical effect of pegylated interferon α-2a in treatment of previously untreated HBeAg-positive chronic hepatitis B patients and related predictive factors[J]. J Clin Hepatol, 2018, 34(5): 995-1000. DOI: 10.3969/j.issn.1001-5256.2018.05.014.
Citation: Lou Xin, Gao YuFeng, Ye Jun, Wang YinQiu, Guan ZiShu, Zou GuiZhou. Clinical effect of pegylated interferon α-2a in treatment of previously untreated HBeAg-positive chronic hepatitis B patients and related predictive factors[J]. J Clin Hepatol, 2018, 34(5): 995-1000. DOI: 10.3969/j.issn.1001-5256.2018.05.014.

高通量测序在肝硬化患者腹水、血清及粪便微生物群检测中的应用

DOI: 10.3969/j.issn.1001-5256.2020.04.042
基金项目: 

中国初级保健基金会佑安肝病艾滋病基金(2017003); 

详细信息
  • 中图分类号: R575.2

Advances in the clinical application of high-throughput sequencing in detecting microbiota in cirrhotic ascites,serum,and feces

Research funding: 

 

  • 摘要: 肝硬化是慢性进展性肝病,且肝硬化患者极易发生感染,尤其腹水、血清、粪便的菌群变化与肝硬化的进展及并发症有关。但是,大多数患者因腹水、血液中的细菌丰度低无法进行有效的细菌培养,因此难以进行全面分析。二代测序技术的高通量和高速度优势可以用于病原体生物学及临床诊断,包括病原体检测和鉴定、菌株分型、微生物组学研究,从而帮助临床医师优化抗菌药物的使用。目前,二代测序技术不断成熟,临床上对微生物群的全基因组进行分析成为可能。

     

  • [1] WOO PC,LAU SK,TENG JL,et al. Then and now:Use of16S r DNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories[J]. Clin Microbiol Infect,2008,14(10):908-934.
    [2] NOBRE SR,CABRAL JE,GOMES JJ,et al. In-hospital mortality in spontaneous bacterial peritonitis:A new predictive model[J].Eur J Gastroenterol Hepatol,2008,20(12):1176-1181.
    [3] ENGELMANN C,KROHN S,PRYWEREK D,et al. Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival[J]. Eur J Gastroenterol Hepatol,2016,28(11):1285-1292.
    [4] HARDICK J,WON H,JENG K,et al. Identification of bacterial pathogens in ascitic fluids from patients with suspected spontaneous bacterial peritonitis by use of broad-range PCR(16S PCR)coupled with high-resolution melt analysis[J]. J Clin Microbiol,2012,50(7):2428-2432.
    [5] LUTZ P,NISCHALKE HD,STRASSBURG CP,et al. Spontaneous bacterial peritonitis:The clinical challenge of a leaky gut and a cirrhotic liver[J]. World J Hepatol,2015,7(3):304-314.
    [6] MINEMURA M,SHIMIZU Y. Gut microbiota and liver diseases[J]. World J Gastroenterol,2015,21(6):1691-1702.
    [7] MARCHESI JR,ADAMS DH,FAVA F,et al. The gut microbiota and host health:A new clinical frontier[J]. Gut,2016,65(2):330-339.
    [8] GOEL A,GUPTA M,AGGARWAL R. Gut microbiota and liver disease[J]. J Gastroenterol Hepatol,2014,29(6):1139-1148.
    [9] RUNYON BA,AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis:An update[J]. Hepatology,2009,49(6):2087-2107.
    [10] DUBOURG G,RAOULT D. Emerging methodologies for pathogen identification in positive blood culture testing[J]. Expert Rev Mol Diagn,2016,16(1):97-111.
    [11] KROHN S,BHM S,ENGELMANN C,et al. Application of qualitative and quantitative real-time PCR,direct sequencing,and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites[J]. J Clin Microbiol,2014,52(5):1754-1757.
    [12] FENG Y,CHEN CL,CHEN TH,et al. Application of nextgeneration sequencing to study ascitic microbiome in cirrhotic patients with or without spontaneous bacterial peritonitis[J]. J Microbiol Immunol Infect,2015,48(5):504-509.
    [13] ENGELMANN C,KROHN S,PRYWEREK D,et al. Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival[J]. Eur J Gastroenterol Hepatol,2016,28(11):1285-1292.
    [14] FAGAN KJ,ROGERS GB,MELINO M,et al. Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection[J]. PLo S One,2015,10(3):e0120642.
    [15] ROGERS GB,van der GAST CJ,BRUCE KD,et al. Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension[J]. PLo S One,2013,8(9):e74884.
    [16] LUTZ P,PARCINA M,BEKEREDJIAN-DING I,et al. Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin[J]. Infection,2014,42(1):175-177.
    [17] SORIANO G,ESPARCIA O,MONTEMAYOR M,et al. Bacterial DNA in the diagnosis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther,2011,33(2):275-284.
    [18] SANTIAGO A,POZUELO M,POCA M,et al. Alteration of the serum microbiome composition in cirrhotic patients with ascites[J]. Sci Rep,2016,6:25001.
    [19] CARO E,FRANCS R,ZAPATER P,et al. Grade of soluble inflammatory response is mainly affected by circulating bacterial DNA concentrations in cirrhosis[J]. Liver Int,2016,36(10):1473-1480.
    [20] SCHNABL B,BRENNER DA. Interactions between the intestinal microbiome and liver diseases[J]. Gastroenterology,2014,146(6):1513-1524.
    [21] OLSZAK T,NEVES JF,DOWDS CM,et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10[J]. Nature,2014,509(7501):497-502.
    [22] BIAGI E,CANDELA M,FAIRWEATHER-TAIT S,et al. Aging of the human metaorganism:The microbial counterpart[J].Age(Dordr),2012,34(1):247-267.
    [23] ZEISSIG S,BLUMBERG RS. Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system[J]. FEBS Lett,2014,588(22):4188-4194.
    [24] IVANOV II,HONDA K. Intestinal commensal microbes as immune modulators[J]. Cel Host Microbe,2012,12(4):496-508.
    [25] CHEN Y,YANG F,LU H,et al. Characteristics of fecal microbial community in patients with cirrhosis[J]. Hepatology,2011,54(2):562-572.
    [26] QIN N,LI A,FANG F,et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature,2014,513(7516):59-64.
    [27] WEI X,YAN X,ZOU D,et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J]. BMC Gastroenterol,2013,13:175.
    [28] BAJAJ JS,BETRAPALLY NS,GILLEVET PM. Decompensated cirrhosis and microbiome interpretation[J]. Nature,2015,525(7569):e1-e2.
    [29] WOODHOUSE CA,PATEL VC,SINGANAGANM A,et al. The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment pharmacol Ther,2018,47(2):192-202.
    [30] GRUMAZ S,STEVENS P,GRUMAZ C,et al. Next-generation sequencing diagnostics of bacteremia in septic patients[J]. Genome Med,2016,8(1):73.
    [31] MARSTON DA,MCELHINNEY LM,ELLIS RJ,et al. Next generation sequencing of viral RNA genomes[J]. BMC Genomics,2013,14:444.
    [32] LONG Y,ZHANG Y,GONG Y,et al. Diagnosis of sepsis with cell-free DNA by next-generation sequencing technology in ICU patients[J]. Arch Med Res,2016,47(5):365-371.
    [33] MURTAZA M,DAWSON SJ,POGREBNIAK K,et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer[J]. Nat Commun,2015,6:8760.
    [34] ROGERS GB,CUTHBERTSON L,HOFFMAN LR,et al. Reducing bias in bacterial community analysis of lower respiratory infections[J]. ISME J,2013,7(4):697-706.
    [35] GOODWIN S,MCPHERSON JD,MCCOMBIE WR. Coming of age:Ten years of next-generation sequencing technologies[J]. Nat Rev Genet,2016,17(6):333-351.
  • 期刊类型引用(37)

    1. 李容容,苟悦,刘宁宁,陈日润,孙鑫,刘成海. 基于临床数据挖掘的中药对抗肿瘤药物相关肝损伤的影响及用药规律探讨. 时珍国医国药. 2024(01): 243-247 . 百度学术
    2. 张倩茹,卢颖,张婉婷,杨艳. 某院急性白血病患者药源性肝损伤临床治疗的回顾性分析. 遵义医科大学学报. 2024(04): 401-407 . 百度学术
    3. 中华医学会,中华医学会杂志社,中华医学会肝病分会药物性肝病学组,中华医学会全科医学分会,中华医学会《中华全科医师杂志》编辑委员会,中国医药生物技术协会药物性肝损伤防治技术专业委员会,中国初级卫生保健基金会药物肝脏安全性专业委员会,中国药物性肝损伤基层诊疗与管理指南制定专家组. 中国药物性肝损伤基层诊疗与管理指南(2024年). 中华全科医师杂志. 2024(08): 813-830 . 百度学术
    4. 郑晖,孙蓉. 药物联合应用对中草药相关肝损伤的影响. 临床肝胆病杂志. 2024(08): 1519-1524 . 本站查看
    5. 李容容,李盟,苟悦,罗琼,吕桦,孙鑫,刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析. 中国药物警戒. 2023(05): 505-510 . 百度学术
    6. 中国医药生物技术协会药物性肝损伤防治技术专业委员会,中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志. 2023(04): 355-384 . 百度学术
    7. 程诗思,杨成明,曾安津. 荆州地区结核病专科医院抗结核药物不良反应分析. 临床合理用药. 2023(22): 147-150 . 百度学术
    8. 江程,李春晓,杨玉晴,郭静. 热毒宁注射液上市后临床安全性文献研究. 中国药事. 2023(11): 1252-1265 . 百度学术
    9. 王双双,熊清芳,胡一帆,陈妙洋,杨永峰. 药物性肝损伤的临床与病理特点分析. 肝脏. 2023(11): 1280-1284 . 百度学术
    10. 孟尧,张萌萌,郭甜甜,赵新颜. 《中国药物性肝损伤诊治指南(2023年版)》更新要点解读. 中国肝脏病杂志(电子版). 2023(04): 1-5 . 百度学术
    11. 马世武,刘成海,刘晓琰,苏明华,李东良,李异玲,陈公英,陈军,陈金军,茅益民,赵景民,郭晓燕,唐洁婷,诸葛宇征,谢青,谢雯,赖荣陶,蔡大川,蔡庆贤. 中国药物性肝损伤诊治指南(2023年版). 胃肠病学. 2023(07): 397-431 . 百度学术
    12. 孙晓楠,吕萌,程国亭. 药物性肝损伤139例回顾性分析. 中南医学科学杂志. 2022(03): 391-394 . 百度学术
    13. 李娜. 肺癌患者化疗后药物性肝损伤的临床特点. 中国医药指南. 2022(16): 22-25 . 百度学术
    14. 劳明珠. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤临床效果和安全性. 临床合理用药杂志. 2022(17): 84-87 . 百度学术
    15. 马万龙,焦运,张旭,丁向春,张平,欧阳花,王梦甜,张乐,徐灵博,杨安宁,姜怡邓. 血清IL-6在人工肝治疗药物性肝损伤预后评估中的价值. 宁夏医科大学学报. 2022(06): 622-629 . 百度学术
    16. 沈婷婷,李光耀,罗琼,李盟,孙鑫,陶艳艳,周祖山,刘成海. 类风湿性关节炎患者应用雷公藤制剂及合并用药所致药物性肝损伤的临床特征分析. 临床肝胆病杂志. 2022(09): 2067-2072 . 本站查看
    17. 马世武,刘成海,刘晓琰,苏明华,李东良,李异玲,陈公英,陈军,陈金军,茅益民,赵景民,郭晓燕,唐洁婷,诸葛宇征,谢青,谢雯,赖荣陶,蔡大川,蔡庆贤. 中国药物性肝损伤诊治指南(2023年版). 胃肠病学. 2022(06): 341-375 . 百度学术
    18. 汪涛,王学伟,蒋元烨,曹勤,季光. 162例药物性肝损伤患者分析. 肝脏. 2021(03): 243-246 . 百度学术
    19. 王艳,王昱,王岚,田秋菊,杨瑞园,李柯鑫,刘立伟,王晓明,王宇,欧晓娟,贾继东,赵新颜. 中草药与西药致药物性肝损伤的临床特征及其预后的对比研究. 肝脏. 2021(04): 364-369 . 百度学术
    20. 杨焕芝,李兴德,陈学平,张仲安,钱彦华,蒋潇,徐艳琼,宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 . 百度学术
    21. 何婷婷,王丽苹,任璐彤,崔延飞,柏兆方,郭玉明,宫嫚,王睿林. 中西药肝损伤临床及病理特征分析. 肝脏. 2021(09): 962-967 . 百度学术
    22. 刘秀兰,李为,郭敏,杜金凤,刘东,李娟. 药物性肝损伤相关医疗损害案例分析. 药物流行病学杂志. 2021(11): 729-734 . 百度学术
    23. 陈凯霞,赵广玉,印登阳,陈宏俊,黄继勋. 三种保肝药治疗化疗引起的DILI的药物经济学评价. 中国实用医药. 2021(35): 188-191 . 百度学术
    24. 罗琼,朱哿瑞,顾宏图,刘坤,陈高峰,邢枫,陶艳艳,刘成海. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较. 临床肝胆病杂志. 2020(03): 596-601 . 本站查看
    25. 蔡春梅. 妊娠早期肝功能异常60例的病因分析及干预. 中国城乡企业卫生. 2020(06): 100-102 . 百度学术
    26. 周力. 中西药所致药物性肝损伤临床及病理特点研究. 临床医药文献电子杂志. 2020(39): 56 . 百度学术
    27. 纪童童,陆海英,谭宁,于岩岩,徐小元. 急、慢性药物性肝损伤临床特征的对比分析. 临床肝胆病杂志. 2020(07): 1556-1561 . 本站查看
    28. 何文昌,张克恭,赵凡惠,郭芮杉,高禄化,黄长形,王临旭. 290例药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2020(04): 540-543 . 百度学术
    29. 李梁,陶应敏,张学敏,谢娟,陈园. 药物性肝损伤患者外周血清HIF1α和COX-2定量检测的临床价值. 肝脏. 2020(08): 848-852 . 百度学术
    30. 李卉,张宏亮,杨天燕,黄振光,刘滔滔,韦芳. 我院125例抗结核药物不良反应报告分析. 中国医药导报. 2020(29): 151-154 . 百度学术
    31. 姜正艳,郑亮. 异甘草酸镁治疗药物性肝损伤临床疗效观察. 世界最新医学信息文摘. 2019(07): 123 . 百度学术
    32. 张惠娟,史祖宣,赵兰芳,高天慧,李健. 56例抗肿瘤药物致肝损伤临床特点分析. 临床肝胆病杂志. 2019(03): 574-578 . 本站查看
    33. 梁栋,董晓锋,张燕,朱晓红,王建斌,刘妲妲,柳伟伟,方圆,王全楚. 98例药物性肝损伤的临床特点及诊疗体会. 肝脏. 2019(04): 389-391 . 百度学术
    34. 黄波,张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 . 百度学术
    35. 郭立杰,张海丛,叶立红,王超,杜婧,伍彦辉. 中西药所致药物性肝损伤临床及病理特点分析. 临床误诊误治. 2019(08): 28-33 . 百度学术
    36. 吴宇宇,袁苏榆,孙四珍,王岁晶,丁洋. 药物性肝损伤诊断治疗进展概述. 药物流行病学杂志. 2018(08): 550-555 . 百度学术
    37. 王建青,叶珺,郜玉峰,杨利琦. 106例药物性肝损伤患者用药回顾性调查. 中国医院药学杂志. 2018(18): 1967-1970 . 百度学术

    其他类型引用(11)

  • 加载中
计量
  • 文章访问数:  844
  • HTML全文浏览量:  25
  • PDF下载量:  167
  • 被引次数: 48
出版历程
  • 出版日期:  2020-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回